Enhancing Access and Affordability
It is a travesty that the balm of life-saving medicine quite often burns a hole in the pocket. A large population still doesn't have access to essential medicines - leading to suffering, disabilities, death and destitution, which could have been preventable.
While every human life is invaluable, the steep cost of essential medicines is a major hurdle that a majority of the population cannot overcome, especially in the developing and under-developed countries.One of our key goals is to improve accessibility, availability and affordability of life-saving medicines for patients no matter where they live.
Our Approach
The gap between the haves and the have-nots is most visible when basic advances in modern medicine are inaccessible to the most vulnerable among us. At Cipla, we are committed to bridging this gap by enhancing access to quality medicines. To achieve this, we invest in R&D to optimise production, utilise the resources responsibly and build key partnerships to boost distribution and leverage technology and innovation.
We also focus on expanding our operations, and increasing the number of markets and products, to amplify the accessibility of life-saving drugs for patients across the world. Combined with our unwavering focus on ESG, we deliver value to all our stakeholders. With a presence in 78 markets, we are leveraging our scale and experience to create a more accessible global healthcare ecosystem.
Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 78 markets*.
*Represent countries/markets where sales are more than USD 0.5 million
Partnerships
Collaboration is multiplication - it allows us to achieve far more than what we can do individually. Partnerships play a critical role in strengthening the accessibility and affordability of vital medicines that lead to better health and a healthier world. Over the years, we have established long-standing partnerships with multiple global funding organisations to advance our goal of providing access to affordable care. Through strategic partnerships, we also broaden our product portfolio of vital and affordable medicines and increase its reach by distributing it to remote geographies.
New Products
In our pursuit of innovation, we conduct extensive research and develop new products to improve global healthcare. We also identify and adopt new product development technologies to increase efficiency and access to life-saving medicines by optimising project timelines, lowering development costs and enabling a smoother manufacturing process after the product launch.
R&D at Cipla
Highlights
1,571 crore
R&D Expenditure1
277
Cumulative ANDAs and NDAs2
2,204
Cumulative DMFs
156
Cumulative US DMFs
101
New products launched
298
Patents granted
Our UN SDGs
1 Operating expenditure including depreciation
2 Includes under approval, tentatively approved and approved ANDAs, NDAs, PEPFAR ANDAs & NDAs for Cipla Limited, InvaGen Pharmaceuticals Inc. and Partners